Unlike traditional target-based screens e.g. assessing enzyme or binding activity, zebrafish drug screening is a whole organism phenotype-based screen. Thus zebrafish screening can probe the entire pathway involved in a particular disease and can screen simultaneously for multiple targets and mechanisms. This makes zebrafish an excellent screening tool for complex diseases or diseases with unclear causes. After the screening, follow-up studies will define a drugs mechanism of action and elucidate its potential drug targets.

· High throughput drug screening:

Juvenile Zebrafish and embryos can be arranged in 96-well microplates for high-throughput drug screening, including drug efficacy detection and behavioral analysis.

·Drug toxicity assessment:

Developing zebrafish embryos and juveniles are transparent and the developing organs can be easily observed under a microscope. This allows simultaneous measurement of drug efficacy and toxicity, including developmental , cardiovascular , and neuro-toxicity.

· One stop service：

ZebraPeutics integrates upstream and downstream industry chain resources to provide one-stop service, including the construction of zebrafish disease models, high-throughput drug screening, efficacy verification and optimization of drug molecular structures, initial screening of drug toxicity, and research on a drugs molecular mechanisms of action.

[Case]